Compare abrdn Income Credit Strategies Fund (ACP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Regeneron Pharmaceuticals Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $641.16M), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 128× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.
| ACP | REGN | |
|---|---|---|
Market Cap | $641.16M | $82.06B |
Sector | Financials | Health |
52-Week High | $5.98 | $812.27 |
52-Week Low | $5.01 | $555.51 |
Dividend Yield | 18.2% | 0.47% |
Enterprise Value | — | $76.77B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
